Positive safety and PK data de-risk ABS-201 and support advancement into MAD. Interim proof-of-concept data in H2 2026 is the next major catalyst. Traders should monitor for enrollment updates and any competitive developments in the hair loss therapeutic space.
Price Chart
Executive Summary
Absci reported positive interim Phase 1 data for ABS-201, an anti-prolactin receptor antibody for androgenetic alopecia (hair loss). The drug was well tolerated with no serious adverse events, and an estimated half-life of at least 65 days supports a convenient dosing schedule. The study has advanced into the multiple ascending dose (MAD) portion, with interim proof-of-concept data expected in H2 2026.
Key Facts
- No serious adverse events reported across all four SAD cohorts (32 participants).
- Estimated half-life of at least 65 days supports dosing two or three times over six months.
- Study advanced into subcutaneous MAD portion in participants with AGA.
- Interim proof-of-concept data anticipated in H2 2026; full data in early 2027.
- ABS-201 targets a large market: ~80 million Americans affected by androgenetic alopecia.
- Preclinical data showed statistically superior hair regrowth vs minoxidil in a mouse model.
Financial Impact
No financial figures provided; early-stage biotech with no approved products or revenue. Market cap ~$1.2B.
Risk Factors
- Interim data are from a small sample (32 participants); results may not be predictive of later-stage trials.
- Proof-of-concept data not expected until H2 2026; stock may be volatile without near-term catalysts.
- Competition from existing treatments (minoxidil, finasteride) and other pipeline candidates.
- ABS-201 is still in Phase 1; regulatory and clinical risks remain high.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3316681 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 10w ago | Institutional Cluster | $9.50 $9.99 | ▲ +5.16% | ▲ +5.60% | $9.18 (−3.37%) |
Jul 6, 2026 16w ago | Insider Buy | $11.33 $10.23 | ▼ −9.71% | ▼ −10.26% | $9.18 (−18.98%) |
Jun 24, 2026 17w ago | 8-K | $10.21 $11.11 | ▲ +8.81% | ▲ +7.25% | $9.18 (−10.09%) |
Jun 24, 2026 17w ago | 424B5 | $10.21 $11.11 | ▲ +8.81% | ▲ +7.25% | $9.18 (−10.09%) |
Jun 24, 2026 17w ago | Press Release | $10.08 $11.11 | ▲ +10.27% | ▲ +8.57% | $9.18 (−8.88%) |
Jun 24, 2026 17w ago | 8-K | $10.08 $11.11 | ▲ +10.27% | ▲ +8.57% | $9.18 (−8.88%) |
Jun 24, 2026 17w ago | Press Release | $10.08 $11.11 | ▲ +10.27% | ▲ +8.57% | $9.18 (−8.88%) |
Apr 23, 2026 26w ago | Press Release | $3.94 $4.98 | ▲ +26.27% | ▲ +25.36% | $9.18 (+132.99%) |
Apr 22, 2026 26w ago | DEFA14A | $3.97 $4.71 | ▲ +18.64% | ▲ +17.16% | $9.18 (+131.23%) |
Mar 24, 2026 30w ago | Press Release | $2.92 $3.15 | ▲ +7.88% | ▲ +8.12% | $9.18 (+214.38%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers